{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:28:34Z","timestamp":1759940914611},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T00:00:00Z","timestamp":1380844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The appropriateness of use of generic instead of brand-name medication remains unresolved and controversial in several areas of medicine. Some evidence suggestive of variations in bioavailability and clinical effectiveness between different formulations make policy decisions occasionally difficult. The use of generic olanzapine is a widely acceptable practice on the basis of quality, safety and efficacy data and has been adopted in several countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>The case of a 14 year old boy with bipolar affective disorder, autism and intellectual disability who had brand-name to generic olanzapine switch associated with rapid deterioration of his mental state is described. This clinical change was not related to any physical illness or other medication adjustment and resolved as rapidly when generic olanzapine was switched back to the brand-name formulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Caution should be exercised when policy for switching from brand-name to generic psychotropic medications are made, especially when using medications off label, in extremes of age and in those patients with co-morbid complicating factors such as intellectual disability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-244x-13-244","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T15:00:57Z","timestamp":1380898857000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study"],"prefix":"10.1186","volume":"13","author":[{"given":"Rani","family":"Samuel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azizah","family":"Attard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinos","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,4]]},"reference":[{"key":"1418_CR1","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/S0149-2918(03)80340-5","volume":"25","author":"PA Meredith","year":"2003","unstructured":"Meredith PA: Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003, 25: 2875-2890. 10.1016\/S0149-2918(03)80340-5.","journal-title":"Clin Ther"},{"key":"1418_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/YIC.0b013e328337910b","volume":"25","author":"HC Margolese","year":"2010","unstructured":"Margolese HC, Wolf Y, Desmarais JE, Beauclair L: Loss of response after switching from brand name to generic formulations. Three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol. 2010, 25: 180-182. 10.1097\/YIC.0b013e328337910b.","journal-title":"Int Clin Psychopharmacol"},{"key":"1418_CR3","first-page":"13","volume":"48","author":"G Borgheini","year":"2010","unstructured":"Borgheini G: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. J Psychosoc Nurs Ment Health Serv. 2010, 48: 13-16.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","volume":"17","author":"JE Desmarais","year":"2011","unstructured":"Desmarais JE, Beauclair L, Margolese HC: Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther. 2011, 17: 750-760. 10.1111\/j.1755-5949.2010.00210.x.","journal-title":"CNS Neurosci Ther"},{"key":"1418_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0272-6386(99)70318-5","volume":"33","author":"S Sabatini","year":"1999","unstructured":"Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH: Drug substitution in transplantation: a national kidney foundation white paper. Am J Kidney Dis. 1999, 33: 389-397. 10.1016\/S0272-6386(99)70318-5.","journal-title":"Am J Kidney Dis"},{"key":"1418_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1185\/030079904125003250","volume":"20","author":"S Layton","year":"2004","unstructured":"Layton S, Barbeau M: Generic replacement of clozapine: a simple decision model from a Canadian perspective. Cuee Med Res Opin. 2004, 20: 453-459. 10.1185\/030079904125003250.","journal-title":"Cuee Med Res Opin"},{"key":"1418_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/14737167.8.6.549","volume":"8","author":"AA Araszkiewicz","year":"2008","unstructured":"Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A: Generic olanzapine: health authority opportunity or nightmare?. Expert Rev Pharmacoecon Outcomes Res. 2008, 8: 549-555. 10.1586\/14737167.8.6.549.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1418_CR8","unstructured":"Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drugs Products - General Considerations. : , http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070124.pdf (Assessed 25 July 2011)"},{"key":"1418_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4088\/JCP.11cr07606","volume":"73","author":"J Goldberg","year":"2012","unstructured":"Goldberg J: A case of akathisia after switching from branded to generic high-dose olanzapine. J Clin Psychiatry. 2012, 73: 497-10.4088\/JCP.11cr07606.","journal-title":"J Clin Psychiatry"},{"key":"1418_CR10","doi-asserted-by":"publisher","first-page":"e23611","DOI":"10.1371\/journal.pone.0023611","volume":"6","author":"A Van der Meersch","year":"2011","unstructured":"Van der Meersch A, Dechartres A, Ravaud P: Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS One. 2011, 6: e23611-10.1371\/journal.pone.0023611.","journal-title":"PLoS One"},{"key":"1418_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.yebeh.2004.05.011","volume":"5","author":"AN Wilner","year":"2004","unstructured":"Wilner AN: Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004, 5: 995-998. 10.1016\/j.yebeh.2004.05.011.","journal-title":"Epilepsy Behav"},{"key":"1418_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3346\/jkms.2009.24.1.7","volume":"24","author":"DS Yim","year":"2009","unstructured":"Yim DS: Simulation of the AUC changes after generic substitution in patients. J Korean Med Sci. 2009, 24: 7-12. 10.3346\/jkms.2009.24.1.7.","journal-title":"J Korean Med Sci"},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1001\/jama.2008.758","volume":"300","author":"AS Kesselheim","year":"2008","unstructured":"Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH: Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008, 300: 2514-2526. 10.1001\/jama.2008.758.","journal-title":"JAMA"},{"key":"1418_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/archinte.1988.00380040046010","volume":"148","author":"S Richton-Hewett","year":"1988","unstructured":"Richton-Hewett S, Foster E, Apstein CS: Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med. 1988, 148: 806-808. 10.1001\/archinte.1988.00380040046010.","journal-title":"Arch Intern Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-244\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:45:51Z","timestamp":1630547151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,4]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-244","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,4]]},"assertion":[{"value":"19 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"244"}}